Transcriptional correlates of the pathological phenotype in a Huntington's disease mouse model

Andrea Gallardo-Orihuela1,2, Irati Hervás-Corpión1,2, Carmen Hierro-Bujalance1,3

  • 1Instituto de Investigación e Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA), Cádiz, Spain.

Scientific Reports
|December 12, 2019
PubMed

Insights

Huntington disease (HD) research reveals that altered gene transcription in the brain correlates with symptom severity in mouse models. This finding may help explain symptom variability in human HD patients.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Huntington disease (HD) is a fatal, incurable neurodegenerative disorder caused by CAG repeat expansion in the huntingtin (HTT) gene.
  • Symptom heterogeneity in HD patients and mouse models suggests additional contributing factors beyond CAG repeat length.

Purpose of the Study:

  • To investigate the relationship between transcriptional alterations and phenotypical traits in a mouse model of Huntington disease (R6/1 strain).
  • To identify potential molecular correlates for the variability in HD symptom manifestation.

Main Methods:

  • Analysis of the R6/1 mouse model to correlate motor and cognitive phenotypical traits with gene expression changes across brain regions (prefrontal cortex, striatum, hippocampus, cerebellum).
  • Focus on specific gene expression patterns, including HD-related genes and those involved in striatal function.

Main Results:

  • Downregulation of HD-related genes (e.g., Penk, Plk5, Itpka) showed tissue-specific correlations with phenotypical traits.
  • Transcriptional dysregulation in the striatum was exacerbated in mice with poorer overall scores, affecting genes like Pde10a, Drd1, Drd2, and Ppp1r1b.
  • Transcripts linked to better outcomes, such as Nfya and genes involved in neuronal development, were also identified.

Conclusions:

  • Altered brain transcription is associated with the manifestation of HD-like symptoms in mouse models.
  • These findings suggest that transcriptional changes contribute to the heterogeneity of HD symptoms and may be relevant to human patients.